Corporate Business Development Director (Biopharma)
Oxford Nanopore Technologies
Location Oxford, UK (Hybrid)
Travel: Monthly
Oxford Nanopore Technologies is a pioneering company in the field of DNA and RNA sequencing, developing innovative nanopore-based technology that enables real-time, accessible, and scalable analysis. With applications spanning research, clinical diagnostics, and industrial settings, Oxford Nanopore is transforming how biological insights are generated and applied worldwide.
We are seeking an experienced Corporate Business Development Director with a strong track record in the biopharma sector to lead and support partnership activities that drive strategic growth.
About the Role
As part of the Business Development team, you will play a central role in building a global ecosystem of partnerships to accelerate the adoption of nanopore sequencing across applied and clinical markets. This role focuses on developing and executing collaborations with biopharmaceutical and biotechnology companies to enable the commercialisation of innovative applications in priority end markets.
Key Responsibilities
What We’re Looking For
This is an opportunity for a commercially driven and strategically minded professional who thrives in a collaborative environment and is motivated to build impactful partnerships that advance cutting-edge genomic technologies.
Apply now to join Oxford Nanopore Technologies and help shape the future of molecular sensing and genomic innovation.
Please note that no terminology in this advert is intended to discriminate on the grounds of a person's gender, marital status, race, religion, colour, age, disability or sexual orientation. Every candidate will be assessed only in accordance with their merits, qualifications and abilities to perform the duties of the job.
#LI-LH1
#LI-hybrid
Oxford Nanopore Technologies: Our goal is to bring the widest benefits to society through enabling the analysis of anything, by anyone, anywhere. The company has developed a new generation of nanopore-based sensing technology for faster, information rich, accessible and affordable molecular analysis. The first application is DNA/RNA sequencing, and the technology is in development for the analysis of other types of molecules including proteins. The technology is used to understand and characterise the biology of humans and diseases such as cancer, plants, animals, bacteria, viruses, and whole environments. With a thriving culture of ambition and strong innovation goals, Oxford Nanopore is a UK headquartered company with global operations and customers in more than 125 countries.
Our goal is to enable the analysis of anything, anywhere, by anyone.
We have developed the world’s first and only nanopore DNA and RNA sequencing platform. It’s a new generation of sequencing technology — the only one to offer: scalability to portable or ultra-high throughput formats, real-time data delivery, and the ability to elucidate rich biological data.
We are aiming to disrupt the way that biological analyses are currently performed, and open up new applications that have a profound, positive impact on society.
Our devices offer real-time analysis, for rapid insights, in fully scalable formats — from pocket to population scale — and the technology is being used in more than 100 countries worldwide.
Founded in 2005 as a spin-out from the University of Oxford, the company now employs more than 600 people from multiple disciplines including nanopore science, molecular biology and applications, informatics, engineering, electronics, manufacturing and commercialisation. The management team, led by CEO Dr Gordon Sanghera, has a track record of delivering disruptive technologies to the market.
